Big Pharma Shakeup: Neurocrine Buys Soleno for Breakthrough Hunger Drug
Neurocrine’s $2.9 Billion Bet: A Strategic Move Into Rare Diseases In a…
Why Eli Lilly’s $3.5 Billion Investment Signals the Future of Obesity Drugs
Eli Lilly is doubling down on its push to dominate the fast-growing…
$170 Billion Patent Cliff Pushes Global Pharma into Renewed Biotech Buying Spree
Global pharmaceutical giants are accelerating efforts to acquire biotech companies and late-stage…